Compare · MDLN vs PLSE
MDLN vs PLSE
Side-by-side comparison of Medline Inc. (MDLN) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.79B, about 28.8x PLSE ($1.76B).
- Over the past year, MDLN is down 5.1% and PLSE is up 57.9% - PLSE leads by 63.0 points.
- MDLN has hit the wire 4 times in the past 4 weeks while PLSE has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 6 for PLSE).
- Company
- Medline Inc.
- Pulse Biosciences Inc
- Price
- $38.67-4.70%
- $25.46-1.64%
- Market cap
- $50.79B
- $1.76B
- 1M return
- +4.15%
- -5.09%
- 1Y return
- -5.10%
- +57.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 6
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest PLSE
- SEC Form 4 filed by Director Zanganeh Mahkam
- SEC Form 4 filed by Director Van Den Broek Richard
- SEC Form 4 filed by Director Duggan Robert W
- SEC Form 4 filed by Director Soni Manmeet Singh
- SEC Form 4 filed by Director Sainz Maria
- Pulse Biosciences Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
- Canaccord Genuity initiated coverage on Pulse Biosciences with a new price target
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026